During 2014-2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently.
A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Confirmed EVD patients were sequentially enrolled and treated with either WHO recommended supportive therapy (control group) from October 10(th) to 30(th), or treated with WHO recommended therapy plus Favipiravir (T-705) from November 1(st) to 10(th), 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.
The overall survival rate in the T-705 treatment group was higher than that of control group (56.4%, 22/39 vs 35.3%, 30/85, P=0.027). Among the 35 patients who finished all designed endpoint observations, the survival rate in T-705 treatment group (64.8%, 11/17) was higher than that of control group (27.8%, 5/18). Furthermore, the average survival time of the treatment group (46.9±5.6 days) was longer than that of the control group (28.9±4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had over a 100 fold viral load reduction, compared to only 16.7% of patients in the control group.
Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD.